Personal preferences for avoiding gynecomastia (Stage 1)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This qualitative study will use semi-structured interviews with men who have high-risk biochemical recurrence of prostate cancer, including men with and without prior androgen-deprivation therapy (ADT) exposure who have experienced breast-related side effects. Interviews will explore perceptions of gynecomastia and other breast-related harms, their impact on daily life and quality of life, and how patients weigh those harms against cancer control. Responses will be analyzed to define a set of attributes and levels that can be used in a later discrete choice experiment (DCE). Separate ethical approval will be sought for the subsequent DCE that uses the attributes developed here.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Men with high-risk BCR PCa but no ADT+/-ARPI experience.
* Men with ADT+/-ARPI experience who have experienced breast-related side effects from this treatment.

Exclusion Criteria:

• Men receiving psychiatric care as a consequence of their prostate cancer diagnosis or treatment thereof.

Where it's running

• Kinghorn Cancer Centre
  Sydney, New South Wales, Australia Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adaptive intraoperative biopsy system for prostate cancer using imaging and metabolic feedback

  Aiming to test a smart biopsy approach that combines preoperative imaging with real-time metabolic signals to guide where to take prostate biopsy cores for better precision in men suspected of prostate cancer.

  Recruiting at 4 sites Shanghai Zhongshan Hospital · Shanghai and 3 other locations · NCT07856017

• MRT-2359 plus apalutamide in advanced prostate cancer

  This Phase 2 trial tests whether taking MRT-2359 with apalutamide can lower PSA in men with castration-resistant prostate cancer.

  Recruiting at 7 sites Phase 2 Monte Rosa Therapeutics, Inc · Los Angeles, California and 13 other locations · NCT07745361

• Predicting prostate cancer response to neoadjuvant darolutamide with a gene biomarker

  This study tests whether a gene-based PCAI ImmunoScore can predict which high-risk localized or locally advanced prostate cancer patients will have minimal residual disease after 90–120 days of darolutamide before surgery.

  Recruiting at 2 sites Phase 2 Region Stockholm · Gothenburg and 1 other locations · NCT07617272

• LaserSAFE: Quick in OR imaging to check margins during prostatectomy

  A new in‑the‑operating‑room imaging method called LaserSAFE is tested to see if it can quickly detect cancer at the edge of the prostate during surgery for patients undergoing robot-assisted prostatectomy.

  Recruiting University College, London · London · NCT07541911

• Early postoperative PSA after prostate removal as a predictor of cancer outcomes

  We will test whether early PSA levels after prostate removal can help predict long-term cancer outcomes in men undergoing radical prostatectomy.

  Recruiting Lithuanian University of Health Sciences · Kaunas, Kauno · NCT07516886

• Epidemiology, diagnosis, and treatment patterns of prostate cancer in Algeria

  This project collects medical and treatment information to see how prostate cancer is diagnosed and managed in Algerian men with confirmed disease.

  Recruiting at 21 sites Société Algérienne de Formation et Recherche en Oncologie · Adrar, Algeria and 23 other locations · NCT07484971

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.